知镜 Cognispect · 医学文献与研究工作台

Orforglipron and the Kidney: A Promise or Disappointment? The Need for Trials Examining Renal Outcomes.

Shah J, Luna-Ceron E, Payan-Schober F, Aimee Hechanova L, Clegg DJ, Palmer BF.
American journal of nephrology · 2026-09-09 · PMID 42715144

文献摘要

Background Orforglipron, the first oral non-peptide GLP-1 receptor agonist, has a pharmacokinetic and formulation profile that may be theoretically attractive for patients with chronic kidney disease (CKD) including hepatic metabolism with minimal renal excretion and removal of potential barriers associated with current injectable and other oral formulations. Summary We utilized a literature search utilizing PubMed/MEDLINE and ClinicalTrials.gov from their respective inceptions through May 2026 to synthesize a review on orforglipron. Phase 3 trials demonstrated significant reductions in hemoglobin A1c, body weight, and cardiovascular risk markers with stable eGFR and no indications of significant renal toxicity. These trials however were not designed or powered to evaluate renal outcomes including eGFR, albuminuria, and kidney failure progression. Additionally, previous trials were noted to have underrepresented or excluded populations of patients with advanced CKD; thus, renal effects are inferential barring further clinical investigation, though a current trial examining kidney and cardiovascular outcomes in patients with both atherosclerosis and CKD is underway. Key message Future CKD-specific trials are necessary to determine the safety, efficacy, and potential integration of orforglipron into nephrology treatment algorithms.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。